Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,964 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04473911 | Haplo Peripheral Blood Sct In GVHD Prevention | completed | Phase 1 | 25 | Zachariah Michael DeFilippOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05703542 | BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 | 24 | Eric Stephen Winer, MDOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT03971799 |
| Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia |
| active not recruiting |
| Phase 1 / Phase 2 |
| 52 |
| Center for International Blood and Marrow Transplant ResearchNETWORK |
| 1 |
| Jul 14, 2025 |
| clinicaltrials |
| NCT04789408 | Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 15 | Kite, A Gilead CompanyINDUSTRY | 2 | Jul 11, 2025 | clinicaltrials |
| NCT04891757 | FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies | active not recruiting | Phase 1 | 144 | Foghorn Therapeutics Inc.INDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | terminated | Phase 1 | 55 | Biomea Fusion Inc.INDUSTRY | 5 | Jul 3, 2025 | clinicaltrials |
| NCT06199557 | A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients(HUVAMER) | recruiting | Phase 1 / Phase 2 | 48 | Haukeland University HospitalOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05442580 | CART-38 in Adult AML and MM Patients | terminated | Phase 1 | 11 | University of PennsylvaniaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07036250 | Clinical Study of U32 in Patients With Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT02446964 | Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia | completed | Phase 1 | 31 | City of Hope Medical CenterOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT05521087 | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias | withdrawn | Phase 1 | 0 | Janssen Research & Development, LLCINDUSTRY | 0 | Jun 22, 2025 | clinicaltrials |
| NCT07028073 | A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 78 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT03724084 | Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement | terminated | Phase 1 / Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2025 | clinicaltrials |
| NCT05248685 | Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Beijing Boren HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06128044 | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia(AMpLify) | terminated | Phase 1 | 12 | Caribou Biosciences, Inc.INDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07014449 | Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 18 | Hangzhou Weben Pharma Co., LtdINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT02257138 | Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06880354 | A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 37 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03844997 | Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 35 | Sudipto Mukherjee, MD, PhD, MPHOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT03031249 | Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia | enrolling by invitation | Phase 1 / Phase 2 | 80 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT03031262 | Efficacy and Safety of Chidamide in CBF Leukemia | active not recruiting | Phase 1 / Phase 2 | 250 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06449482 | Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy | terminated | Phase 1 / Phase 2 | 6 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT04752163 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT03537599 | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 4 | Sumithira VasuOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT04730258 | A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML(TWT-202) | active not recruiting | Phase 1 / Phase 2 | 72 | Treadwell Therapeutics, IncINDUSTRY | 3 | May 18, 2025 | clinicaltrials |
| NCT05447663 | A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 8 | Novartis PharmaceuticalsINDUSTRY | 3 | May 16, 2025 | clinicaltrials |
| NCT03063944 | STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy | completed | Phase 1 | 37 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03286114 | Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab | terminated | Phase 1 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT06634394 | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | recruiting | Phase 1 | 39 | Aptevo TherapeuticsINDUSTRY | 1 | May 11, 2025 | clinicaltrials |
| NCT04081259 | LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy | completed | Phase 1 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT05038644 | XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia | terminated | Phase 1 | 22 | Ehab L AtallahOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT03560908 | Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation | withdrawn | Phase 1 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT03008187 | MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia(Diamond-01) | completed | Phase 1 / Phase 2 | 73 | Menarini GroupINDUSTRY | 4 | Apr 29, 2025 | clinicaltrials |
| NCT06297941 | Study of REM-422 in Patients With AML or Higher Risk MDS | recruiting | Phase 1 | 100 | Remix TherapeuticsINDUSTRY | 2 | Apr 23, 2025 | clinicaltrials |
| NCT06462365 | Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) | recruiting | Phase 1 | 36 | Tr1X, Inc.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT03813147 | Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2025 | clinicaltrials |
| NCT01892371 | Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 73 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT03038230 | MCLA-117 in Acute Myelogenous Leukemia | terminated | Phase 1 | 80 | Merus B.V.INDUSTRY | 5 | Apr 6, 2025 | clinicaltrials |
| NCT03755414 | Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation | completed | Phase 1 | 55 | Washington University School of MedicineOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06911710 | The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors(CAR-T) | recruiting | Phase 1 / Phase 2 | 90 | Tianjin Medical University General HospitalOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT00588991 | Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2025 | clinicaltrials |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | terminated | Phase 1 | 272 | IGM Biosciences, Inc.INDUSTRY | 5 | Mar 28, 2025 | clinicaltrials |
| NCT04277442 | Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia | completed | Phase 1 | 1 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2025 | clinicaltrials |
| NCT06245746 | UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia | recruiting | Phase 1 | 9 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT02193958 | Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies | completed | Phase 1 / Phase 2 | 55 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | completed | Phase 1 / Phase 2 | 277 | Karyopharm Therapeutics IncINDUSTRY | 5 | Mar 19, 2025 | clinicaltrials |
| NCT05947344 | A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) | recruiting | Phase 1 | 84 | Zhejiang ACEA Pharmaceutical Co. Ltd.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT05662904 | Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML(GALAXY33) | not yet recruiting | Phase 1 | 12 | German Cancer Research CenterOTHER | 1 | Mar 14, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 20, 2025source: clinicaltrials